| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
BCRP (breast cancer resistance protein), also known as ABCG2. ML753286 is a potent inhibitor for BCRP but does not inhibit P-glycoprotein (P-gp), organic anion-transporting polypeptide (OATP), or major cytochrome P450s (CYPs). This high selectivity makes it a useful tool for dissecting BCRP-specific functions.
|
|---|---|
| ln Vitro |
For P-gp-, BCRP-, and OATP-mediated transport, respectively, ML753286 has IC50 values of >30, 0.6, and 39.0 μM[1].
In vitro, ML753286 shows IC50 values of >30 microM for P-gp-mediated transport, 0.6 microM for BCRP-mediated transport, and 39.0 microM for OATP-mediated transport, confirming its potent and selective BCRP inhibition. It has high permeability and low to medium clearance in liver S9 fractions across species, and is stable in plasma. |
| ln Vivo |
At 25 mg/kg PO or 20 mg/kg IV, ML753286 (25- or 50-mg/kg PO; 10 or 20 mg/kg IV; 0.083-24 hours) appears to totally suppress Bcrp functions in rats. The plasma tmax values in Bcrp KO rats, WT rats pre-administered 25 mg/kg ML753286, and WT rats pre-administered 50 mg/kg ML753286 were 1.4, 4.0, and 4.1 hours, respectively[1].
In vivo, ML753286 appears to completely inhibit Bcrp functions in rats at 25 mg/kg oral (PO) or 20 mg/kg intravenous (IV) administration. In Bcrp knockout and wild-type rats, plasma tmax values were 1.4, 4.0, and 4.1 hours, respectively. A single dose (50-300 mg/kg oral) effectively inhibits Bcrp functions in mice. |
| Enzyme Assay |
In vitro ADME assays are conducted using standard protocols. For transporter inhibition, membrane vesicles expressing human BCRP, P-gp, or OATP are incubated with probe substrates and varying concentrations of ML753286. Following incubation, transporter-mediated substrate uptake is measured and IC50 values are calculated by nonlinear regression using software like GraphPad Prism.
|
| Cell Assay |
Standard cell-based transport assays are performed using polarized cell monolayers (e.g., Caco-2 or MDCK cells overexpressing ABC transporters). Cells are seeded on permeable supports, and ML753286 is added to either apical or basolateral compartment. After incubation, samples are collected and analyzed by LC-MS/MS to determine apparent permeability and efflux ratios.
|
| Animal Protocol |
Animal studies are conducted in rodents (mice and rats). ML753286 is administered via oral gavage (25-50 mg/kg) or intravenous injection (10-20 mg/kg). Serial blood samples are collected at predetermined time points (0.083-24 hours). Plasma is separated and analyzed by LC-MS/MS. Bcrp function is assessed using sulfasalazine as a probe substrate.
|
| ADME/Pharmacokinetics |
ML753286 demonstrates favorable preclinical PK properties. It has high permeability (across Caco-2 or MDCK cell monolayers) and low to medium intrinsic clearance in rodent and human liver S9 fractions. It is stable in plasma across species. The tmax in rats ranges from 1.4-4.1 hours. Oral bioavailability and systemic clearance data confirm suitability for in vivo BCRP inhibition studies.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation in rodent models indicates that ML753286 is well-tolerated at effective doses (25-50 mg/kg PO and 10-20 mg/kg IV). As a highly selective BCRP inhibitor with minimal off-target interactions (no significant P-gp, OATP, or CYP inhibition), its toxicity profile is expected to be favorable. However, comprehensive safety studies including chronic toxicity and genotoxicity are not publicly available as this is a research tool compound.
|
| References | |
| Additional Infomation |
ML753286 is a Ko143 analog developed for preclinical ADME characterization of BCRP function. It is a useful selective inhibitor to evaluate BCRP/Bcrp activity in vitro and in rodent model systems. The compound has been used to demonstrate that Bcrp inhibition affects the oral absorption and clearance of sulfasalazine in rodents. It has not entered clinical trials and is not FDA-approved; it remains a research-grade chemical tool for transporter studies.
|
| Molecular Formula |
C20H25N3O3
|
|---|---|
| Molecular Weight |
355.43
|
| Related CAS # |
ML753286;1699720-89-2
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~25 mg/mL (~70.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8135 mL | 14.0675 mL | 28.1349 mL | |
| 5 mM | 0.5627 mL | 2.8135 mL | 5.6270 mL | |
| 10 mM | 0.2813 mL | 1.4067 mL | 2.8135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
